Nomura: China pharmaceuticals roadmap may support sector development

Nomura’s Jialin Zhang says China’s roadmap for innovative, global-facing pharmaceuticals appears to lay a foundation for sector development, citing the 15th Five-Year Plan target for listed pharma companies’ R&D-to-sales ratio.